"Medical quick reading society" Pianzihuang announced another price increase of Beida pharmaceutical's net profit in 2019 by 35%

[January 21, 2020 / list of medical information] 15 provinces and cities adjusted the price of consumables; Aidi pharmaceutical science and technology innovation board IPO completed the inquiry; revolution proposed IPO raised $100 million; suofanidine advanced pancreatic neuroendocrine tumor phase 3 succeeded; AstraZeneca imfinzi combination treatment of HCC was qualified as an orphan drug; 60% of the clinical trial results were not published in accordance with the provisions of FDA Daily fresh medicine news, speed reading club and you pay attention to! On the 21st, Shanghai Sunshine pharmaceutical purchasing network announced the results of the national drug centralized purchase According to the announcement, according to the provisions of the national drug centralized procurement document (gy-yd2019-2), the joint procurement office carried out the drug centralized procurement work and announced the results of the selection today The specific implementation date will be announced separately (announcement of Shanghai Sunshine pharmaceutical purchasing website) On the 20th, Shanghai Sunshine pharmaceutical purchasing network released the notice on further optimizing the rules of price negotiation for medical devices on the Internet, which greatly adjusted the prices of consumables in 15 provinces and cities, including Beijing, Tianjin, Jiangsu, Zhejiang and Guangdong (Shanghai sunshine medicine purchasing network) Shanghai Stock Exchange science and Technology Innovation Board announced on January 20 that Aidi pharmaceutical's listing application has completed the inquiry The company submitted an IPO application in October last year, with a proposed financing amount of 746 million yuan, of which about 600 million yuan will be used in new drug research and development and related projects in the field of antiviral and anti-tumor (Medical Mission Hills) Recently, revolution announced that it plans to raise $100 million in IPO to develop new small molecule inhibitors for cancer treatment It is reported that the company is currently developing drugs for the "cutting-edge target" of cancer treatment, mainly targeting Ras and mTOR important signal pathways in tumor treatment (chuangjianhui) On the 20th, Beida Pharmaceutical Co., Ltd released the 2019 performance forecast, and its net profit is expected to increase by 20% ~ 35% over the same period of last year, with a profit of 200 ~ 225 million yuan According to the announcement, the sales volume of beta pharmaceutical's ektini will continue to increase in 2019, with the expected operating revenue and net profit attributable to shareholders of the listed company rising year on year (medicine cube) On the 21st, pianzehuang announced that the retail price of pianzehuang tablets in the domestic market will be increased from 530 yuan / tablet to 590 yuan / tablet, the supply price will be increased by about 40 yuan / tablet, and the supply price in the overseas market will be increased by about 5.80 USD / tablet According to the announcement, the price of the film increased again, mainly due to the increase of raw materials and labor costs (Pianzihuang notice) On the 20th, he Huang medicine announced that the mid-term analysis of the sanet-p study of suvantinib for advanced pancreatic neuroendocrine tumors reached the main end point, and the study will be terminated in advance Sofantini is a new oral tyrosine kinase inhibitor independently developed by Hehuang pharmaceutical, which has dual activities of anti angiogenesis and immune regulation (American news agency) On the 20th, AstraZeneca announced that the combination therapy of imfinzi and tremelimumab has been awarded the orphan drug qualification of treating HCC by the US FDA Currently, imfinzi has not been approved in any country to treat HCC alone or in combination with tremelimumab (Sina pharmaceutical) Hengrui registered to launch an open label, non randomized, single arm phase III extension study for its PD1 carrizumab It is reported that the test will be carried out in the Cancer Hospital of the Chinese Academy of Medical Sciences, Jiangsu cancer hospital and Beijing Cancer Hospital (medicine cube) Recently, gma301, a new humanized monoclonal antibody developed by Hongyun Huaning, has been approved for clinical trial in China and is used for the treatment of pulmonary hypertension It is reported that pulmonary hypertension is an extremely malignant disease with poor prognosis and high mortality, which can be called "cancer" in cardiovascular diseases (medicine cube)